This reduced hepatic steatosis could be attributed to a reduction in de novo lipogenesis promoted by chrysin, as gene analysis showed that the marked increase in FAS expression prompted by a HFD was no longer present upon chrysin treatment. The gene discussed is FAS; the disease is Hepatic steatosis.